NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer... The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this population.
- Mechanism
- Curator reviewed
NP50301 is an estrogen ester compound believed to act by multiple mechanisms, including influencing the health of the cornea, the meibomian glands and the conjunctiva.
- Primary indication
- Investigated for use/treatment in eye disorders/infections.Curator reviewed
- Code names
- NP50301
Resolves to
What you can answer from here — as of March 06, 2025
Which drugs share a target with NP-50301, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account